Serious adverse events · people with primary hyperparathyroidism
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
SAEs
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
1 finding from 1 review
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs
1 finding from 1 review
SAEs
1 finding from 1 review
Serious adverse events
1 finding from 1 review
SAEs
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review